admin, Author at Evercyte - Forever is just enough

23 05, 2024

hTERT immortalized ASC for large-scale EV production

hTERT immortalized ASC for large-scale EV production

By admin|2026-02-07T10:24:58+00:00May 23rd, 2024|Extracellular vesicles, mesenchymal stromal cells, recent highlights EV, telomerized cells|

Recent publication showcasing our ASC/TERT1 cells as EV production system May 23rd, 2024, Vienna, Austria Our telomerized human adipose derived MSC (ASC/TERT1, also

29 04, 2024

Evercyte proudly introduces the EVscale™ platform

By admin|2026-02-07T10:29:56+00:00April 29th, 2024|EVscale, Extracellular vesicles, recent highlights EV|

Evercyte proudly introduces the EVscale™ platform April 29th, 2024, Vienna, Austria The collaborative effort of Evercyte, Phoenestra, and TAmiRNA has yielded the EVscale™ platform,

16 02, 2024

Newly published study featuring our PODO/TERT256 cell line

By admin|2026-02-07T10:29:35+00:00February 16th, 2024|PODO/TERT256, telomerized cells|

Recent publication showcasing our PODO/TERT256 telomerized cell line February 16th, 2024, Vienna, Austria Our telomerized human podocyte cells (PODO/TERT256) were employed in an

7 12, 2023

Evercyte contributing to reduce animal testing at key events

By admin|2026-02-07T10:29:13+00:00December 7th, 2023|3Rs, cell line development, conferences, GCCP|

Evercyte contributing to reduce animal testing at key events December 7th, 2023, Vienna, Austria We participated as an invited attendee at

22 11, 2023

Evercyte Showcases Expertise in Japan’s Pharma Landscape

By admin|2026-02-07T10:28:46+00:00November 22nd, 2023|cell line development, collaboration, EV cell factories, Extracellular Vesicles, mesenchymal stromal cells|

Evercyte Showcases Expertise in Japan’s Pharma Landscape November 22nd, 2023, Vienna, Austria We recently visited Summit Pharmaceuticals International to present our

27 10, 2023

Participation to the first MOVE symposium

By admin|2026-02-07T10:28:27+00:00October 27th, 2023|Extracellular vesicles and ageing, mesenchymal stromal cells|

We participated to the first MOVE symposium in Malaga, Spain October 27th, 2023, Vienna, Austria We participated to the first MOVE

19 09, 2023

Participation to the Small New World 2.0 meeting

By admin|2026-02-07T10:28:04+00:00September 19th, 2023|Extracellular vesicles and ageing, mesenchymal stromal cells|

We participated to the Small New World 2.0 meeting in Graz, Austria September 12th, 2023, Vienna, Austria We participated to the

4 08, 2023

RPTEC/TERT1 relevant kidney-on-a-chip model

By admin|2026-02-07T10:27:45+00:00August 4th, 2023|3Rs, collaboration, organ-on-a-chip, RPTEC/TERT1|

Collaboration with Nortis to establish human kidney-on-a-chip model August 4th, 2023. Vienna, Austria Our telomerized Human Renal Proximal Tubular Epithelial cells (RPTEC/TERT1) were used in collaboration with

9 04, 2021

MDimune and Evercyte form partnership for developing tumor-targeting EVs

MDimune and Evercyte form partnership for developing tumor-targeting EVs

By admin|2021-09-17T15:46:31+00:00April 9th, 2021|Extracellular vesicles|

MDimune and Evercyte form partnership for developing tumor-targeting EVs April 1, 2021, Seoul, Korea and Vienna, Austria MDimune Inc. and Evercyte GmbH announced a

9 04, 2021

Knock-out of CD46 in RPTEC/TERT1 cells
Knock-out of CD46 in RPTEC/TERT1 cells

Knock-out of CD46 in RPTEC/TERT1 cells

By admin|2021-04-09T08:41:15+00:00April 9th, 2021|recent highlights gene editing|

Knock-out of CD46 in RPTEC/TERT1 cells Application: gene editing of human telomerized cells with CRISPR/Cas9 knock-out of CD46 in RPTEC/TERT1 cells using CRISPR

About admin

hTERT immortalized ASC for large-scale EV production

MDimune and Evercyte form partnership for developing tumor-targeting EVs

Knock-out of CD46 in RPTEC/TERT1 cells

Title